DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Obach, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Obach, R. S.

Vol. 28, Issue 9, 1069-1076, September 2000

Metabolism of Ezlopitant, a Nonpeptidic Substance P Receptor Antagonist, in Liver Microsomes: Enzyme Kinetics, Cytochrome P450 Isoform Identity, and In Vitro-In Vivo Correlation

R. Scott Obach

Drug Metabolism Department, Pfizer Central Research, Groton, Connecticut

The enzyme kinetics of the metabolism of ezlopitant in liver microsomes from various species have been determined. The rank order of the species with regard to the in vitro intrinsic clearance of ezlopitant was monkey guinea pig > rat dog > human. CJ-12,764, a benzyl alcohol analog, was observed as a major metabolite, and a dehydrogenated metabolite (CJ-12,458) was equally important in human liver microsomes. Scale-up of the liver microsomal intrinsic clearance data and correcting for both serum protein binding and nonspecific microsomal binding yielded predicted hepatic clearance values that showed a good correlation with in vivo systemic blood clearance values. Including microsomal binding was necessary to achieve agreement between hepatic clearance values predicted from in vitro data and systemic clearance values measured in vivo. Cytochrome P450 (CYP) 3A4, 3A5, and 2D6 demonstrated the ability to metabolize ezlopitant to CJ-12,458 and CJ-12,764. However, in liver microsomes, the CYP3A isoforms appear to play a substantially more important role in the metabolism of ezlopitant than CYP2D6, as assessed through the use of CYP-specific inhibitors, correlation to isoform-specific marker substrate activities, and appropriate scale-up of enzyme kinetic data generated in microsomes containing individual heterologously expressed recombinant CYP isoforms. The apparent predominance of CYP3A over CYP2D6 is consistent with observations of the pharmacokinetics of ezlopitant in humans in vivo.

Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
C. Prakash, J. O'Donnell, and S. C. Khojasteh-Bakht
Metabolism, Pharmacokinetics, and Excretion of a Nonpeptidic Substance P Receptor Antagonist, Ezlopitant, in Normal Healthy Male Volunteers: Characterization of Polar Metabolites by Chemical Derivatization with Dansyl Chloride
Drug Metab. Dispos., July 1, 2007; 35(7): 1071 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Venkatakrishnan and R. S. Obach
IN VITRO-IN VIVO EXTRAPOLATION OF CYP2D6 INACTIVATION BY PAROXETINE: PREDICTION OF NONSTATIONARY PHARMACOKINETICS AND DRUG INTERACTION MAGNITUDE
Drug Metab. Dispos., June 1, 2005; 33(6): 845 - 852.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. A. Krauser and F. P. Guengerich
Cytochrome P450 3A4-catalyzed Testosterone 6{beta}-Hydroxylation Stereochemistry, Kinetic Deuterium Isotope Effects, and Rate-limiting Steps
J. Biol. Chem., May 20, 2005; 280(20): 19496 - 19506.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J.-S. Wang, X. Wen, J. T. Backman, and P. J. Neuvonen
Effect of Albumin and Cytosol on Enzyme Kinetics of Tolbutamide Hydroxylation and on Inhibition of CYP2C9 by Gemfibrozil in Human Liver Microsomes
J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 43 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. S. Obach
Mechanism of Cytochrome P4503A4- and 2D6-Catalyzed Dehydrogenation of Ezlopitant as Probed with Isotope Effects Using Five Deuterated Analogs
Drug Metab. Dispos., December 1, 2001; 29(12): 1599 - 1607.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. V. Kuperman, A. S. Kalgutkar, A. Marfat, R. J. Chambers, and T. E. Liston
Pharmacokinetics and Metabolism of a Cysteinyl Leukotriene-1 Receptor Antagonist from the Heterocyclic Chromanol Series in Rats: In Vitro-In Vivo Correlation, Gender-Related Differences, Isoform Identification, and Comparison with Metabolism in Human Hepatic Tissue
Drug Metab. Dispos., November 1, 2001; 29(11): 1403 - 1409.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. S. Obach
Cytochrome P450-Catalyzed Metabolism of Ezlopitant Alkene (CJ-12,458), a Pharmacologically Active Metabolite of Ezlopitant: Enzyme Kinetics and Mechanism Of an Alkene Hydration Reaction
Drug Metab. Dispos., July 1, 2001; 29(7): 1057 - 1067.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.